

Utilization of Autogenous Platelet Gel for Enhancement of Healing of Diabetic Foot Wounds

Dr. Hazim Abdul Kareem Altaee¹ and Dr. Hasan Wadea Hasan²

¹M.B.Ch.B., F.I.C.M.S. \ (General Surgery) Iraqi Ministry of Defense, Al-Hussain Military Hospital, Baghdad, Iraq

²M.B.Ch.B., C.A.B.M.S. \ (General Surgery) Iraqi Ministry of Defense, Al-Hussain Military Hospital, Baghdad, Iraq

Abstract: Diabetic ulcers have a multifactorial cause and are known for the gradualness with which they mend and for the protection from treatment. Autogenous platelet gel is an item whose adequacy has never been tried in controlled examinations in the treatment of diabetic ulcers. We directed a controlled perception on the adequacy of autogenous platelet gel, notwithstanding the standard treatment for the treatment of constant diabetic foot ulcers. 14 diabetic patients with ulcers in the lower furthest points were contemplated, doled out by randomization to standard treatment or standard treatment in addition to utilization of the platelet gel. The two gatherings were similar for age, sex, length of diabetes, and glycosylated hemoglobin. At standard perception, the region of the ulcers was not altogether unique in the platelet gel treatment bunch contrasted with the benchmark group (273 ± 156 versus 170 ± 89 mm³). The 5-week decrease in the pace of ulcer surface was more prominent in patients treated with platelet gel contrasted with those experiencing conventional treatment (71.9% versus 9.2% separately, $p < 0.05$). Taking everything into account, the platelet gel has demonstrated to be compelling and safe in quickening the mending of diabetic ulcers.

Keywords: Diabetic ulcers, platelet gel.

INTRODUCTION

Diabetic ulcers have a multifactorial starting point and are known for the gradualness with which they mend and for the protection from treatment. These kinds of ulcers effectively face confusion, for example, gangrene and contamination, and removal is frequently fundamental (American Diabetes Association, 1999). New information about the organic procedures engaged with shutting ulcers and tissue recovery has prompted an improvement in the treatment of diabetic ulcers. The topical use of recombinant development factors got from platelets has prompted a few triumphs in the treatment of incessant bedsores and diabetic foot ulcers (Singer AJ, 1999; Wieman TJ, 1998). Platelet gel is an autogenous item that is easy to plan and cheap, which has demonstrated to be without chance and viable in quickening the conclusion of careful injuries (Marx RE, *et al.*, 1998).

Besides, a review observational examination proposes that platelet gel is additionally powerful in the treatment of diabetic ulcers (Margolis DJ, 2001). The challenges in controlling conceivable choice inclinations and efficient contrasts between bunches speak to an outlandish constraint of observational examinations; as indicated by our findings, the adequacy of autogenous platelet gel has never been tried in a controlled report. Subsequently, we directed a controlled report on the adequacy of the use of autogenous platelet gel notwithstanding the standard treatment, for the treatment of interminable diabetic foot ulcers.

MATERIALS AND METHODS

14 patients from the diabetic foot medical procedure were contemplated. The patients qualified for the examination were experiencing Wagner (Wagner FW, 1998) grade II/III ulcers, present for at any rate two months without any indications of contamination at the hour of enrollment. The members they gave their educated assent and were doled out by randomization to one of two gatherings: standard treatment or standard treatment with the expansion of the utilization of the autogenous platelet gel.

In the first part of the day, the patients experienced a scaled-down blood test of around 45 mL at our Transfusion Center. The platelets were isolated by centrifugation at 1200 rpm for 15 minutes to acquire a platelet concentrate (4-6 times the basal worth). From platelet concentrate, by second centrifugation, a platelet-rich plasma and a platelet-poor plasma were gotten. Platelet-poor plasma was utilized to give autogenous thrombin; from platelet-rich plasma, in any case, autogenous platelet gel was acquired after initiation by calcium gluconate and autogenous thrombin.

As a list of fringes vasculopathy, the lower leg/arm file (Winsor file) was determined for all investigation members and, and to maintain a strategic distance from a lopsidedness between the two treatment gatherings, a case stratification technique was applied dependent on this parameter before continuing with randomization. The

investigation members were visited week after week on various days, relying upon the kind of treatment rehearsed: our endpoint was the result of the ulcer after perception following 5 weeks of treatment. The region of the ulcer was determined considering the ulcer as an oval whose distances across are individually the longest and most brief side of the ulcer (Houghton E, 1997).

The region of the ulcer was estimated toward the start of the treatment (beginning territory) and following 5 weeks (last zone); the decrease rate was determined as [initial region (mm²) - last region (mm²)]/introductory zone (mm²) (Johnson JD. 1995). The administrators who estimated the ulcers were unconscious of their separate medicines. Constant factors were looked at utilizing nonparametric tests, due to the non-ordinariness of their appropriation. Fisher's definite test and McNemar's test were utilized to look at the extent. Contrasts are considered factually huge with a $p < 0.05$ for the two-sample test.

RESULTS

The two treatment bunches are tantamount by age, sexual orientation, length of diabetes, and glycosylated hemoglobin esteems. All patients, aside from one for each gathering, had a lower leg/arm record more noteworthy than 0.90. The midpoints of the underlying regions were higher in the platelet gel treatment gathering (273 ± 156 versus 170 ± 89 mm³), yet the thing that matters was not measurably huge. The 5-week decrease rate was essentially more prominent in patients treated with platelet gel (Table 1). Every one of the 7 patients allocated to the platelet gel improved. 2 ulcers totally shut and for the staying 5, the region decreased essentially when contrasted and the beginning one: from 273 ± 156 to 80 ± 75 mm², $p < 0.05$. In standard treated ulcers, one ulcer shut, one intensified, and the zones of the staying 5 ulcers remained significantly unaltered (170 ± 89 versus 162 ± 168 mm², $p = 0.858$).

Table 1 Patient clinical data and dimensions of ulcers by treatment group

	Platelet gel (n=7)	Standard treatment (n=7)	P
Gender (men)	4 (57.2%)	2 (28,5%)	0.591
Age (years)	61.2 ± 9.3	58.1 ± 7.8	0.529
Duration of diabetes (years)	16.2 ± 7.7	19.6 ± 9.8	0.488
Ankle/arm index	0.96 ± 0.17	1.01 ± 0.11	0.348
HbA _{1c} (%)	9.4 ± 1.8	8.8 ± 1.7	0.445
Initial area (mm ²)	274 ± 155	170 ± 89	0.157
Area at 5 weeks (mm ²)	80 ± 75	162 ± 168	0.268
Difference between areas (mm ²)	193 ± 117	9 ± 107	0.011
Reduction rate (%)	71.9 ± 22.5	9.2 ± 67.8	0.038
Complete healing or reduction of at least 50% *	5 (71.4%)	2 (28.6%)	0.285
* OR towards standard treatment 6.2 (95%, CI 0.6 -63.0)			

DISCUSSION AND CONCLUSION

As far as anyone is concerned, this work comprises the main controlled examination on the viability and security of autogenous platelet gel for the treatment of diabetic foot ulcers. No antagonistic impacts were seen in patients treated with platelet gel, and a critical decrease in the width of the ulcer was seen in the platelet gel-treated group, yet not in the standard treatment gathering. We utilized a five-week perception time as an endpoint. This time, the interim is regularly too short to even think about expecting a huge improvement in diabetic foot ulcers with standard treatment alone. Platelets are the principle wellspring of a group of development factors (GF): epidermal GF, changing GF, and platelet-derived GF, which are totally engaged with the natural procedures of ulcer recuperating and tissue recovery (2). Platelet

gel is an autogenous item that doesn't open the patient to iatrogenic diseases or safe responses; its creation is snappy and basic and is extensively more affordable when contrasted and the expenses of recombinant development factors (3). The most grounded proof for the viability of the platelet gel for the treatment of diabetic foot ulcers originates from an enormous observational examination that has reflectively evaluated the effect of the utilization of platelet gel on the advancement of diabetic ulcers, over a 32-week time frame (5). In contrast to controlled examinations, observational investigations, particularly if review, are dependent upon choice inclination and fitting control of methodical contrasts between treatment bunches isn't constantly doable. In our examination, the control of determination inclinations and fundamental bewildering factors

were acquired by arbitrarily relegating patients to two treatment gatherings and utilizing a standard and totally equivalent treatment convention in the two gatherings aside from the utilization of the platelet gel.

One potential constraint of the investigation is that, in spite of the irregular task, the size of the ulcers was more noteworthy in the treatment bunch than in the benchmark group, in any case, the distinctions were not factually critical, and, regardless, this could have influenced the information just in the feeling of an underestimation of the effect of the gel.

Our outcomes on controlled perceptions, in spite of the fact that got on a little gathering of patients, bolster the security and viability of the platelet gel notwithstanding the standard treatment, in quickening the recuperating procedure of ulcers in the diabetic foot, diminishing the expenses and inconveniences of patients. All together for the viability of the autogenous platelet gel to be unequivocally settled, in any case, perceptions on bigger and longer enduring examples are expected to assess the effect on basic end focuses, for example, complete recuperating of ulcers and counteraction of removals.

REFERENCES

1. American Diabetes Association. "Consensus development conference on diabetic wound care." *Diabetes Care* 22 (1999): 1354–1360.
2. Singer AJ, Clark RA. "Cutaneous wound healing." *New England Journal of Medicine* 341.10 (1999): 739–746.
3. Wieman TJ, Janice M, Yachin S. "Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers." *Diabetes Care* 21 (1998): 822–827.
4. Marx RE, et al. "Platelet-rich plasma: Growth factor enhancement for bone graft." *Journal of Oral and Maxillofacial Surgery* 56 (1998): 855–859.
5. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. "Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers." *Diabetes Care* 24 (2001): 483–488.
6. Wagner FW Jr. "Treatment of diabetic foot." *Comprehensive Therapy* 10.4 (1984): 29–38.
7. Houghton E, Kippen C. "Current methods of measuring ulcers. A review." *Journal of the American Podiatric Medical Association* 87.8 (1997): 358–359.
8. Johnson JD. "Using ulcer surface area and volume to document wound size." *Journal of the American Podiatric Medical Association* 85.2 (1995): 91–95.

Source of support: Nil; **Conflict of interest:** Nil.

Cite this article as:

Altaee, H. A. K. & Hasan, H. W. "Utilization of Autogenous Platelet Gel for Enhancement of Healing of Diabetic Foot Wounds" *Sarcouncil Journal of Medicine and Surgery* 5.2 (2026): pp 36-38.